ORIGINAL PAPER
Construction and validation of a diagnostic model for dermatomyositis based on the LASSO algorithm
1
Sanming First Hospital Affiliated to Fujian Medical University, China
These authors had equal contribution to this work
Submission date: 2024-02-22
Final revision date: 2024-11-08
Acceptance date: 2024-11-25
Publication date: 2025-05-21
Cent Eur J Immunol 2025;(2):219-231
KEYWORDS
ABSTRACT
Introduction:
Dermatomyositis (DM) is the most prevalent disease among myositis patients. The immune response is crucial in DM development. Bioinformatics research on immune-related genes in DM is limited. This study attempted to construct a diagnostic model and investigate immune characteristics of immune-related differentially expressed genes (DEGs), which could aid in DM diagnosis.
Material and methods:
GSE46239 and GSE39454 datasets were from the GEO database, and batch effects were eliminated for use as the DM training set. DEG were identified and enrichment analysis was conducted between DM and normal samples. Intersection of DEGs and immune-related genes yielded immune-related DEGs, which were utilized to generate a PPI network. The diagnostic model was built by the LASSO method. The diagnostic model and effectiveness of model genes were evaluated through GSE143323. The correlation between immune cell infiltration in DM and diagnostic genes was analyzed. Finally, expression levels of HLA genes in DM and their correlation with diagnostic genes were examined.
Results:
A total of 350 DEGs were identified. Seventy-one immune-related DEGs were screened. LASSO regression identified 5 immune-related DEGs (ACKR1, DHX58, IRF7, ISG15, and PSMB8) for constructing the DM diagnostic model. The model showed good effectiveness in training and validation sets (AUC of 0.99 and 0.958, respectively), and 5 immune-related DEGs also exhibited good effectiveness (AUC > 0.784). Diagnostic genes in DM were associated with M1 macrophages, M2 macrophages, resting dendritic cells, and certain HLA genes.
Conclusions:
We constructed a DM diagnostic model using ACKR1, DHX58, IRF7, ISG15, and PSMB8, which were closely related to immune cells and HLA. This model could contribute to research in DM diagnosis.
Dermatomyositis (DM) is the most prevalent disease among myositis patients. The immune response is crucial in DM development. Bioinformatics research on immune-related genes in DM is limited. This study attempted to construct a diagnostic model and investigate immune characteristics of immune-related differentially expressed genes (DEGs), which could aid in DM diagnosis.
Material and methods:
GSE46239 and GSE39454 datasets were from the GEO database, and batch effects were eliminated for use as the DM training set. DEG were identified and enrichment analysis was conducted between DM and normal samples. Intersection of DEGs and immune-related genes yielded immune-related DEGs, which were utilized to generate a PPI network. The diagnostic model was built by the LASSO method. The diagnostic model and effectiveness of model genes were evaluated through GSE143323. The correlation between immune cell infiltration in DM and diagnostic genes was analyzed. Finally, expression levels of HLA genes in DM and their correlation with diagnostic genes were examined.
Results:
A total of 350 DEGs were identified. Seventy-one immune-related DEGs were screened. LASSO regression identified 5 immune-related DEGs (ACKR1, DHX58, IRF7, ISG15, and PSMB8) for constructing the DM diagnostic model. The model showed good effectiveness in training and validation sets (AUC of 0.99 and 0.958, respectively), and 5 immune-related DEGs also exhibited good effectiveness (AUC > 0.784). Diagnostic genes in DM were associated with M1 macrophages, M2 macrophages, resting dendritic cells, and certain HLA genes.
Conclusions:
We constructed a DM diagnostic model using ACKR1, DHX58, IRF7, ISG15, and PSMB8, which were closely related to immune cells and HLA. This model could contribute to research in DM diagnosis.
REFERENCES (40)
1.
Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N (2018): Dermatomyositis: Current concepts. Clin Dermatol 36: 450-458.
2.
Dalakas MC, Hohlfeld R (2003): Polymyositis and dermatomyositis. Lancet 362: 971-982.
3.
Tournadre A, Miossec P (2013): A critical role for immature muscle precursors in myositis. Nat Rev Rheumatol 9: 438-442.
4.
DeWane ME, Waldman R, Lu J (2020): Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol 82: 267-281.
5.
Shao C, Li S, Sun Y, et al. (2020): Clinical characteristics and prognostic analysis of Chinese dermatomyositis patients with malignancies. Medicine (Baltimore) 99: e21899.
6.
Adler BL, Christopher-Stine L (2018): Triggers of inflammatory myopathy: insights into pathogenesis. Discov Med 25: 75-83.
7.
Saraswat N, Verma R, Neema S, Kumar S (2018): A case of capecitabine-induced dermatomyositis. Indian J Pharmacol 50: 350-353.
8.
Gao X, Han L, Yuan L, et al. (2014): HLA class II alleles may influence susceptibility to adult dermatomyositis and polymyositis in a Han Chinese population. BMC Dermatol 14: 9.
9.
Lahouti AH, Christopher-Stine L (2015): Polymyositis and dermatomyositis: novel insights into the pathogenesis and potential therapeutic targets. Discov Med 19: 463-470.
10.
Greenberg SA (2007): A gene expression approach to study perturbed pathways in myositis. Curr Opin Rheumatol 19: 536-541.
11.
Schultz HY, Dutz JP, Furukawa F, et al. (2015): From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013. J Invest Dermatol 135: 7-12.
12.
Ghirardello A, Zampieri S, Tarricone E, et al. (2011): Cutting edge issues in polymyositis. Clin Rev Allergy Immunol 41: 179-189.
13.
Agapito G, Arbitrio M (2022): Microarray data analysis protocol. Methods Mol Biol 2401: 263-271.
14.
Xu A, Wang C, Sun S (2014): Screening candidate genes associated with bladder cancer using DNA microarray. Mol Med Rep 10: 3087-3091.
15.
Li X, Gong J, Meng H, et al. (2016): Investigating molecular mechanisms for rhamnetin in oxidative damaged cardiomyocytes by microarray data analysis. Minerva Cardioangiol 64: 586-594.
16.
Yang ZQ, Liu YJ, Zhou XL (2020): An integrated microarray analysis reveals significant diagnostic and prognostic biomarkers in pancreatic cancer. Med Sci Monit 26: e921769.
17.
Peng QL, Zhang YM, Yang HB, et al. (2016): Transcriptomic profiling of long non-coding RNAs in dermatomyositis by microarray analysis. Sci Rep 6: 32818.
18.
Xie S, Luo H, Zhang H, et al. (2018): Discovery of key genes in dermatomyositis based on the gene expression omnibus database. DNA Cell Biol. DOI: 10.1089/dna.2018.4256.
19.
Xiao L, Xiao W, Lin S (2021): Ten genes are considered as potential biomarkers for the diagnosis of dermatomyositis. PLoS One 16: e0260511.
21.
Leek JT, Johnson WE, Parker HS, et al. (2012): The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28: 882-883.
22.
Fernandez-Ruiz R, Niewold TB (2022): Type I interferons in autoimmunity. J Invest Dermatol 142 (3 Pt B): 793-803.
23.
Jiang J, Zhao M, Chang C, et al. (2020): Type I interferons in the pathogenesis and treatment of autoimmune diseases. Clin Rev Allergy Immunol 59: 248-272.
24.
Zhao X, Si S (2023): Five genes as diagnostic biomarkers of dermatomyositis and their correlation with immune cell infiltration. Front Immunol 14: 1053099.
25.
Borges NH, Godoy TM, Kahlow BS (2021): Onset of dermatomyositis in close association with COVID-19-a first case reported. Rheumatology (Oxford) 60 (SI): SI96.
26.
Baccala R, Hoebe K, Kono DH, et al. (2007): TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 13: 543-551.
27.
Torres-Ruiz J, Carrillo-Vazquez DA, Padilla-Ortiz DM, et al. (2020): TLR expression in peripheral monocyte subsets of patients with idiopathic inflammatory myopathies: association with clinical and immunological features. J Transl Med 18: 125.
28.
Aljabban J, Syed S, Syed S, et al. (2020): Investigating genetic drivers of dermatomyositis pathogenesis using meta-analysis. Heliyon 6: e04866.
29.
Liu R, Shen L, Lin C, et al. (2020): MiR-1587 regulates DNA damage repair and the radiosensitivity of CRC cells via targeting LIG4. Dose Response 18: 1559325820936906.
30.
Zhou L, Sun S, Xu L, et al. (2019): DExH-Box helicase 58 enhances osteoblast differentiation of osteoblastic cells via Wnt/beta-Catenin signaling. Biochem Biophys Res Commun 511: 307-311.
31.
Chen X, Lian D, Zeng H (2023): Single-cell profiling of peripheral blood and muscle cells reveals inflammatory features of juvenile dermatomyositis. Front Cell Dev Biol 11: 1166017.
32.
Salajegheh M, Kong SW, Pinkus JL, et al. (2010): Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 67: 53-63.
33.
de Jesus AA, Hou Y, Brooks S, et al. (2020): Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest 130: 1669-1682.
34.
Peng QL, Zhang YL, Shu XM, et al. (2015): Elevated serum levels of soluble CD163 in polymyositis and dermatomyositis: associated with macrophage infiltration in muscle tissue. J Rheumatol 42: 979-987.
35.
Yin R, Wang G, Zhang L, et al. (2021): Dermatomyositis: immunological landscape, biomarkers, and potential candidate drugs. Clin Rheumatol 40: 2301-2310.
37.
Thompson C, Piguet V, Choy E (2018): The pathogenesis of dermatomyositis. Br J Dermatol 179: 1256-1262.
38.
Waschbisch A, Schwab N, Ruck T, et al. (2010): FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol 225: 137-142.
40.
Wang D, Lei L (2021): Interleukin-35 regulates the balance of Th17 and Treg responses during the pathogenesis of connective tissue diseases. Int J Rheum Dis 24: 21-27.
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
